Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 2/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218998 | 0.87 | CA2 (0.52) | CA2 | |
| Tetrahydrofuran SCHEMBL4701367 | 0.72 | LMNA (0.32) | CA2SMN1; SMN2LMNACRHBPCRHR2 | |
| SCHEMBL329648 | 0.68 | CA2 (0.44) | CA2LMNAHTTTSHRITGB2 | |
| SCHEMBL7988825 | 0.66 | CA2 (0.42) | CA2LMNAHTTTSHR | |
| SCHEMBL329649 | 0.66 | CA2 (0.42) | CA2SMN1; SMN2HTTKMT2ATSHR | |
| SCHEMBL5864109 | 0.66 | CA2 (0.54) | CA2HTT | |
| SCHEMBL11505174 | 0.65 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL1760696 | 0.65 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| Tetrahydrofuran SCHEMBL28300630 | 0.64 | PTGES2 (0.43) | CA2KMT2AGAA | |
| Anthraquinone SCHEMBL28163102 | 0.63 | MEN1 (0.60) | SMN1; SMN2LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222192-B8 | HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1222192-B8 | HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1222192-B1 | HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1222192-B1 | HEXAHYDROFURO¬2,3-B FURAN-3-YL-N- 3-¬(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO -1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARM LTD (IE) | 2008-06-18 | — | — | EP | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-7157495-B2 | Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2007-01-02 | — | — | US | disclosed |
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2005-11-24 | — | — | US | disclosed |
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2005-11-24 | — | — | US | disclosed |
| CN-1191256-C | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) aminol]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC PHARM LTD (IE) | 2005-03-02 | — | — | CN | disclosed |
| US-6649651-B1 | AIDS; human T-cell lymphoma/leukemia virus or lymphadenopathy associated virus treatment | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-18 | — | — | US | disclosed |
| US-6649651-B1 | AIDS; human T-cell lymphoma/leukemia virus or lymphadenopathy associated virus treatment | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-11-18 | — | — | US | disclosed |
| CN-1407987-A | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) aminol]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | TIBOTEC NV (IE) | 2003-04-02 | — | — | CN | disclosed |
| EP-1222192-A1 | HEXAHYDROFURO[2,3-B]FURAN-3-YL-N- 3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | Tibotec Pharmaceuticals Ltd. (IE) | 2002-07-17 | — | — | EP | disclosed |
| EP-1222192-A1 | HEXAHYDROFURO[2,3-B]FURAN-3-YL-N- 3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYL CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | Tibotec Pharmaceuticals Ltd. (IE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025240-A1 | HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001025240-A1 | HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261364-A1 | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor | HPN, DNPEP, DPEP1 | CA2 2491/4885SMN1; SMN2 1552/4885LMNA 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.